Losartan Potassium Tablets, 25 Mg Tablet
Product Images NDC 59746-333

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium Tablets, 25 Mg (NDC 59746-333). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Jubilant Cadista Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Potassium, Usp (Structure)

Chemical structure of losartan potassium, depicted with its molecular components including a tetrazole ring and chlorinated imidazole ring, indicating the active ingredient in Losartan potassium Tablets.*

FDA Label Image

Figure 1 (Figure1)

A line graph comparing the percentage of patients with a primary endpoint over a 66-month study period between Atenolol (dotted line) and Losartan Potassium (solid line). The graph shows adjusted risk reduction of 13% with a p-value of 0.021, plotting percentage of patients on the y-axis and study months on the x-axis.*

FDA Label Image

Figure 2 (Figure2)

A line graph comparing the percentage of patients experiencing a fatal stroke over time between atenolol and losartan potassium. The x-axis represents the study duration in months, and the y-axis shows the percentage of patients with fatal stroke. The graph indicates an adjusted risk reduction of 25% with losartan potassium compared to atenolol, with a statistical significance of p=0.001.*

FDA Label Image

Figure 3 (Figure3)

Figure 3 displays a forest plot of primary endpoint events within demographic subgroups comparing losartan potassium and atenolol. It shows hazard ratios with 95% confidence intervals for primary composite events and stroke (fatal/non-fatal) by age, gender, race, ISH, diabetes, and history of cardiovascular disease, with symbols proportional to sample size and favoring either losartan or atenolol on the x-axis.*

FDA Label Image

Figure 4.jpg (Figure4)

A line graph comparing the percentage of patients with an event over 48 months between those taking Losartan Potassium and a placebo. The graph shows a risk reduction of 16.1% with a p-value of 0.022, with the Losartan Potassium group represented by a solid line and the placebo group by a dashed line.*

FDA Label Image

Label-25-mg (Label 25mg)

Label for Losartan Potassium Tablets, USP 25 mg from Jubilant Cadista Pharmaceuticals Inc. The label specifies 30 tablets in the package marked for prescription use only. It includes storage instructions, dosage note, and is marked as made in Bangladesh. The label shows the NDC 59746-333-30 and contains barcode identifiers.*

FDA Label Image

Label-50-mg (Label 50mg)

Label for Losartan Potassium Tablets, USP 50 mg, oral tablet dosage form. The label states each coated tablet contains 50 mg of losartan potassium. Marketed by Jubilant Cadista Pharmaceuticals Inc. The package contains 30 tablets. Includes storage instructions and a note to dispense with patient information leaflets. Printed barcodes and NDC 59746-334-30 are visible.*

FDA Label Image

Label-100-mg (Label 100mg)

Label for Losartan Potassium Tablets, USP, 100 mg, oral tablet. The label indicates a bottle containing 30 tablets marketed by Jubilant Cadista Pharmaceuticals Inc. It includes storage instructions, the NDC number 59746-335-30, and the Cadista logo. The label specifies dispensing with an accompanying patient information leaflet.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.